Alexander Pickett
Managing Director Juvenescence
Seminars
Tuesday 27th January 2026
Choosing the Right Indication When Aging isn’t a Disease: Navigating Regulatory Complexities, Optimizing Trial Design, & Identifying Appropriate Indications to Accelerate the Development of Aging Therapies
9:30 am
- 12:30 pm
The aging therapeutics field faces a fundamental challenge: aging itself is not classified as a disease, complicating drug development pathways and regulatory approval. Identifying appropriate indications linked to aging that offer clear, measurable endpoints and feasible regulatory routes is crucial to advancing effective therapies. In this 3-hour workshop, we will explore strategic methods on selecting target populations and indications that optimize trial success:
- Identifying age-associated diseases with fast regulatory paths and measurable clinical endpoints by focusing on functional outcomes that enable accelerated approval
- Selecting target populations that show early biomarker shifts, even with modest symptom improvement to demonstrate efficacy within shorter trial durations
- Avoiding the pitfalls of overgeneralizing ‘aging’ in regulatory strategy by tailoring indications and endpoints to specific disease contexts
